165 related articles for article (PubMed ID: 36708743)
1. Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry.
Saladini F; Giammarino F; Maggiolo F; Ferrara M; Cenderello G; Celesia BM; Martellotta F; Spagnuolo V; Corbelli GM; Gianotti N; Santoro MM; Rusconi S; Zazzi M; Castagna A;
Int J Antimicrob Agents; 2023 Mar; 61(3):106737. PubMed ID: 36708743
[TBL] [Abstract][Full Text] [Related]
2. In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations.
Saladini F; Giammarino F; Hosseini BA; Giannini A; Boccuto A; Dragoni F; Vicenti I; Shafer RW; Zazzi M
J Antimicrob Chemother; 2021 Jan; 76(1):130-134. PubMed ID: 32974670
[TBL] [Abstract][Full Text] [Related]
3. Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates.
Asante-Appiah E; Lai J; Wan H; Yang D; Martin EA; Sklar P; Hazuda D; Petropoulos CJ; Walworth C; Grobler JA
Antimicrob Agents Chemother; 2021 Nov; 65(12):e0121621. PubMed ID: 34570651
[TBL] [Abstract][Full Text] [Related]
4. Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressure.
Brenner BG; Oliveira M; Ibanescu RI; Routy JP; Thomas R
J Antimicrob Chemother; 2023 Aug; 78(8):1921-1928. PubMed ID: 37303226
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
Sterrantino G; Borghi V; Callegaro AP; Bruzzone B; Saladini F; Maggiolo F; Maffongelli G; Andreoni M; De Gennaro M; Gianotti N; Bagnarelli P; Vergori A; Antinori A; Zazzi M; Zaccarelli M;
Int J Antimicrob Agents; 2019 Apr; 53(4):515-519. PubMed ID: 30769200
[TBL] [Abstract][Full Text] [Related]
6. Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing.
Melikian GL; Rhee SY; Varghese V; Porter D; White K; Taylor J; Towner W; Troia P; Burack J; Dejesus E; Robbins GK; Razzeca K; Kagan R; Liu TF; Fessel WJ; Israelski D; Shafer RW
J Antimicrob Chemother; 2014 Jan; 69(1):12-20. PubMed ID: 23934770
[TBL] [Abstract][Full Text] [Related]
7. Cell culture selections reveal favourable drug resistance profiles for doravirine and islatravir.
Brenner BG; Oliveira M; Ibanescu RI; Routy JP; Thomas R
J Antimicrob Chemother; 2021 Jul; 76(8):2137-2142. PubMed ID: 33855437
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of doravirine cross-resistance in HIV-infected adults who failed first-line ART in China, 2014-18.
Sun Z; Lan Y; Liang S; Wang J; Ni M; Zhang X; Yu F; Chen M; Zhang H; Yan L; Cai W; Lan G; Ma Y; Zhang F
J Antimicrob Chemother; 2022 Mar; 77(4):1119-1124. PubMed ID: 35134966
[TBL] [Abstract][Full Text] [Related]
9. Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens.
Maggi P; Ricci ED; Cicalini S; Pellicanò GF; Celesia BM; Vichi F; Cascio A; Sarchi E; Orofino G; Squillace N; Madeddu G; De Socio GV; Bargiacchi O; Molteni C; Masiello A; Saracino A; Menzaghi B; Falasca K; Taramasso L; Di Biagio A; Bonfanti P
BMC Infect Dis; 2023 Apr; 23(1):227. PubMed ID: 37059996
[TBL] [Abstract][Full Text] [Related]
10. Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance.
Rhee SY; Schapiro JM; Saladini F; Zazzi M; Khoo S; Shafer RW
AIDS Res Ther; 2023 Feb; 20(1):8. PubMed ID: 36750835
[TBL] [Abstract][Full Text] [Related]
11. Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants.
Smith SJ; Pauly GT; Akram A; Melody K; Ambrose Z; Schneider JP; Hughes SH
J Acquir Immune Defic Syndr; 2016 Aug; 72(5):485-91. PubMed ID: 27124362
[TBL] [Abstract][Full Text] [Related]
12. Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine.
Balamane M; Varghese V; Melikian GL; Fessel WJ; Katzenstein DA; Shafer RW
Antimicrob Agents Chemother; 2012 Aug; 56(8):4522-4. PubMed ID: 22664973
[TBL] [Abstract][Full Text] [Related]
13. Variable antiviral activity of islatravir against M184I/V mutant HIV-1 selected during antiretroviral therapy.
Aulicino PC; Sharma S; Truong K; Kukunoor V; Ghei K; Arazi-Caillaud S; Taicz M; Bologna R; Mangano A; Kimata JT
J Antimicrob Chemother; 2024 Feb; 79(2):370-374. PubMed ID: 38153245
[TBL] [Abstract][Full Text] [Related]
14. Application of Structure-based Methods to Analyze Resistance Mutations for Chemically Diverse Non-Nucleoside Reverse Transcriptase Inhibitors.
Tabassum T; Azeem SM; Muwonge AN; Frey KM
Curr HIV Res; 2020; 18(4):283-291. PubMed ID: 32493197
[TBL] [Abstract][Full Text] [Related]
15. Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)-infected patients.
Scheibe K; Urbańska A; Jakubowski P; Hlebowicz M; Bociąga-Jasik M; Raczyńska A; Szymczak A; Szetela B; Łojewski W; Parczewski M
Antivir Ther; 2021 May; 26(3-5):69-78. PubMed ID: 35485331
[TBL] [Abstract][Full Text] [Related]
16. Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.
Xu HT; Colby-Germinario SP; Asahchop EL; Oliveira M; McCallum M; Schader SM; Han Y; Quan Y; Sarafianos SG; Wainberg MA
Antimicrob Agents Chemother; 2013 Jul; 57(7):3100-9. PubMed ID: 23612196
[TBL] [Abstract][Full Text] [Related]
17. Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors.
Clemente T; Galli L; Lolatto R; Gagliardini R; Lagi F; Ferrara M; Cattelan AM; Focà E; Di Biagio A; Cervo A; Calza L; Maggiolo F; Marchetti G; Cenderello G; Rusconi S; Zazzi M; Santoro MM; Spagnuolo V; Castagna A;
BMJ Open; 2024 Feb; 14(2):e080606. PubMed ID: 38341206
[TBL] [Abstract][Full Text] [Related]
18. HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa.
Kityo C; Thompson J; Nankya I; Hoppe A; Ndashimye E; Warambwa C; Mambule I; van Oosterhout JJ; Wools-Kaloustian K; Bertagnolio S; Easterbrook PJ; Mugyenyi P; Walker AS; Paton NI;
J Acquir Immune Defic Syndr; 2017 Jun; 75(2):e45-e54. PubMed ID: 28129253
[TBL] [Abstract][Full Text] [Related]
19. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
[TBL] [Abstract][Full Text] [Related]
20. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
Gallien S; Charreau I; Nere ML; Mahjoub N; Simon F; de Castro N; Aboulker JP; Molina JM; Delaugerre C
J Antimicrob Chemother; 2015 Feb; 70(2):562-5. PubMed ID: 25344807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
